NovoCure Ltd (NVCR) stock
NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/3031% below fair value
$11.14−0.16 (-1.42%)
Close on Nov 17, 2026Market cap $1.30BP/E –Yield –
NovoCure total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
NovoCure's total debt was $25.00M at Sep 30, 2026. For fiscal 2025 it was $195.05M, up 100.5% from the year before. Over ten years it grew 23.7% a year on average. The highest annual figure on record is $568.82M in fiscal 2023.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $195.05M | +100.5% |
| FY2024 | Dec 31, 2024 | $97.30M | -82.9% |
| FY2023 | Dec 31, 2023 | $568.82M | +0.6% |
| FY2022 | Dec 31, 2022 | $565.51M | +0.6% |
| FY2021 | Dec 31, 2021 | $562.22M | +30.8% |
| FY2020 | Dec 31, 2020 | $429.91M | +187.7% |
| FY2019 | Dec 31, 2019 | $149.42M | +0.1% |
| FY2018 | Dec 31, 2018 | $149.30M | +53.3% |
| FY2017 | Dec 31, 2017 | $97.37M | +1.1% |
| FY2016 | Dec 31, 2016 | $96.30M | +315.8% |
| FY2015 | Dec 31, 2015 | $23.16M | – |
| FY2014 | Dec 31, 2014 | $0 | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $25.00M | -95.6% |
| Q4 FY2025 | Dec 31, 2025 | $195.05M | -65.7% |
| Q4 FY2024 | Dec 31, 2024 | $97.30M | -82.8% |
| Q1 FY2024 | Mar 31, 2024 | $569.65M | +0.6% |
| Q4 FY2023 | Dec 31, 2023 | $568.82M | +0.6% |
| Q3 FY2023 | Sep 30, 2023 | $567.99M | +0.6% |
| Q2 FY2023 | Jun 30, 2023 | $567.15M | +0.6% |
| Q1 FY2023 | Mar 31, 2023 | $566.32M | +0.6% |
| Q4 FY2022 | Dec 31, 2022 | $565.51M | +0.6% |
| Q3 FY2022 | Sep 30, 2022 | $564.68M | +0.6% |
| Q2 FY2022 | Jun 30, 2022 | $563.85M | +0.6% |
| Q1 FY2022 | Mar 31, 2022 | $563.03M | +0.6% |
| Q4 FY2021 | Dec 31, 2021 | $562.22M | +30.8% |
| Q3 FY2021 | Sep 30, 2021 | $561.39M | – |
| Q2 FY2021 | Jun 30, 2021 | $560.56M | +274.9% |
| Q1 FY2021 | Mar 31, 2021 | $559.58M | +274.4% |
| Q4 FY2020 | Dec 31, 2020 | $429.91M | +187.7% |
| Q3 FY2020 | Sep 30, 2020 | $0 | -100.0% |
| Q2 FY2020 | Jun 30, 2020 | $149.51M | +0.1% |
| Q1 FY2020 | Mar 31, 2020 | $149.47M | +0.1% |
| Q4 FY2019 | Dec 31, 2019 | $149.42M | +0.1% |
| Q3 FY2019 | Sep 30, 2019 | $149.38M | +0.1% |
| Q2 FY2019 | Jun 30, 2019 | $149.34M | +0.1% |
| Q1 FY2019 | Mar 31, 2019 | $149.31M | +0.1% |
| Q4 FY2018 | Dec 31, 2018 | $149.30M | +53.3% |
| Q3 FY2018 | Sep 30, 2018 | $149.23M | +53.8% |
| Q2 FY2018 | Jun 30, 2018 | $149.20M | +54.2% |
| Q1 FY2018 | Mar 31, 2018 | $149.16M | +54.6% |
| Q4 FY2017 | Dec 31, 2017 | $97.37M | +1.1% |
| Q3 FY2017 | Sep 30, 2017 | $97.05M | – |
| Q2 FY2017 | Jun 30, 2017 | $96.77M | – |
| Q1 FY2017 | Mar 31, 2017 | $96.49M | – |
| Q4 FY2016 | Dec 31, 2016 | $96.30M | – |
See a number that looks wrong?